Policy & Regulation
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
19 December 2025 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) reported on Friday that its pivotal Phase II FALKON trial in fibrodysplasia ossificans progressiva (FOP) did ...
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
19 December 2025 - Curasight A/S (CPH:CURAS), a Denmark-based clinical stage radiopharmaceuticals company, announced on Thursday that the first patient has been successfully and safely dosed in the Ph...
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
18 December 2025 - Clywedog Therapeutics Inc, a US-based clinical-stage biotechnology company, announced on Wednesday the activation of all clinical centres and patient dosing in its international Pha...
PRISM BioLab partners with Talus Bioscience to address TF and PPI targets
18 December 2025 - PRISM BioLab Co Ltd, a discovery and development biotechnology company based in Japan, announced on Wednesday that it has formed a collaboration with Talus Bioscience Inc, a US-base...
Thryv Therapeutics reports positive Phase 1 results for THRV-1268
18 December 2025 - Canada-based clinical-stage biotechnology company Thryv Therapeutics Inc on Wednesday reported encouraging results from a recently completed Phase 1 clinical study evaluating THRV-1...
Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients
17 December 2025 - Biopharmaceutical company Avacta Therapeutics (AIM: AVCT) on Wednesday reported positive preliminary Phase 1b data for faridoxorubicin (AVA6000) in patients with salivary gland canc...